Not recruiting
Pleural mesothelioma malignant recurrent
Not recruitingRegistered drugNo placebo
Study of Pembrolizumab and Lenvatinib for Patients with Malignant Pleural Mesothelioma in Second and Third Line Treatment
Registered drugNo placebo
- Disease:Pleural mesothelioma malignant recurrent
- Substances:LenvatinibPembrolizumab
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Lenvatinib
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
